Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499512 | 0.93 | ALDH1A1 (0.47) | MEN1KMT2AMGLLSRD5A2 | |
| SCHEMBL9132367 | 0.85 | KMT2A (0.52) | ALOX5THRATHRBKMT2A | |
| SCHEMBL9133875 | 0.81 | CYP4A11 (0.57) | MGLL | |
| SCHEMBL9132885 | 0.80 | ESR1 (0.49) | THRBMEN1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL27692231 | 0.78 | THRA (0.46) | THRATHRBMEN1KMT2AMGLL | |
| SCHEMBL4678555 | 0.77 | ALOX5 (0.41) | ALOX5THRATHRBMEN1KMT2A | |
| SCHEMBL9132340 | 0.76 | PARP10 (0.45) | MEN1KMT2AMGLL | |
| SCHEMBL8803172 | 0.76 | DRD4 (0.50) | ALOX5MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL8804583 | 0.76 | DRD4 (0.51) | ALOX5MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL411370 | 0.76 | TAAR1 (0.45) | ALOX5MEN1KMT2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710159-A1 | CATALYST COMPONENTS FOR PROPYLENE POLYMERIZATION | W. R. Grace & Co. - Conn. (US) | 2020-09-23 | — | — | EP | claimed |
| US-8344079-B2 | Molar ratio modifications to larger polyolefin catalysts | BASF CORPORATION (US) | 2013-01-01 | — | — | US | claimed |
| JP-2011508053-A | — | — | 2011-03-10 | — | — | JP | claimed |
| EP-2242776-A1 | MOLAR RATIO MODIFICATIONS TO LARGER POLYOLEFIN CATALYSTS | BASF Corporation (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009088596-A1 | MOLAR RATIO MODIFICATIONS TO LARGER POLYOLEFIN CATALYSTS | BASF CATALYSTS LLC (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090171044-A1 | MOLAR RATIO MODIFICATIONS TO LARGER POLYOLEFIN CATALYSTS | BASF CATALYSTS LLC (US) | 2009-07-02 | — | — | US | claimed |
| US-20260103548-A1 | PROCESS FOR PRODUCING POLYPROPYLENE-ETHYLENE RANDOM COPOLYMER RESIN WITH SUSTAINABLE REACTOR OPERABILITY | W. R. GRACE & CO.-CONN. | 2026-04-16 | — | — | US | disclosed |
| US-20250235842-A1 | GAS-PHASE PROCESS FOR MAKING POLYPROPYLENE RANDOM COPOLYMERS | W.R. GRACE & CO.-CONN (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250145745-A1 | HIGH MFR POLYPROPYLENE FOR MELTBLOWN NONWOVEN APPLICATIONS | W. R. GRACE & CO.-CONN. | 2025-05-08 | — | — | US | disclosed |
| US-12240925-B2 | Process for preparing solid catalyst components for olefin polymerization | W. R. GRACE & CO.- CONN. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240392047-A1 | CATALYST COMPONENT FOR PROPYLENE POLYMERIZATION WITH IMPROVED CATALYST PERFORMANCE | W.R. GRACE & CO.-CONN (US) | 2024-11-28 | — | — | US | disclosed |
| CN-119013320-A | High MFR polypropylene for melt blown nonwoven applications | 格雷斯公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240343840-A1 | PROCESS FOR PRODUCING POLYOLEFIN GRANULAR RESIN WITH INCREASED SETTLED BULK DENSITY | W.R. GRACE & CO.-CONN. (US) | 2024-10-17 | — | — | US | disclosed |
| US-20040260039-A1 | Process for producing organic compound epoxy resin composition, cured article obtained from the epoxy resin, and semiconductor device obtained with epoxy resin | MITSUI CHEMICALS, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-0972776-B1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | MITSUI CHEMICALS INC (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0950649-B1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | MITSUI CHEMICALS INC (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6153794-A | Phosphine sulfide, a manufacturing process therefor and use thereof | MITSUI CHEMICALS, INC. (JP) | 2000-11-28 | — | — | US | disclosed |
| US-6130346-A | ESTERIFICATION, CARBONATION, SULFONATION, ETHERIFICATION | MITSUI CHEMICALS, INC. (JP) | 2000-10-10 | — | — | US | disclosed |
| EP-0972776-A1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | Mitsui Chemicals, Inc. (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0950649-A1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | Mitsui Chemicals, Inc. (JP) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240925-B2 | Process for preparing solid catalyst components for olefin polymerization | POF1B, PPOX, OGFOD1 | ALOX5 727/4885THRA 2684/4885THRB 3700/4885 |
| US-20260103548-A1 | PROCESS FOR PRODUCING POLYPROPYLENE-ETHYLENE RANDOM COPOLYMER RESIN WITH SUSTAINABLE REACTOR OPERABILITY | CCT4, PTGER1, TCP1 | ALOX5 355/4885THRA 1345/4885THRB 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.